Sensus Healthcare, Inc.
SRTS Healthcare Medical Devices
Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024. In the quarter to June 2026, revenue fell 68.7%, EPS fell 783.3% and free cash flow fell 201.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SRTS
Sensus Healthcare, Inc. (SRTS) EV/Sales
As of 16 October 2026, Sensus Healthcare, Inc. (SRTS) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.6× (November 2023) to 7.5× (March 2021); the current reading is higher than 31% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.8× | (23.30%) |
| FY2024 | 2.3× | 143.47% |
| FY2023 | 0.9× | (56.18%) |
| FY2022 | 2.2× | (46.86%) |
| FY2021 | 4.1× | (28.17%) |
| FY2020 | 5.7× | 223.68% |
| FY2019 | 1.8× | (51.24%) |
| FY2018 | 3.6× | 8.75% |
| FY2017 | 3.3× | (6.36%) |
| FY2016 | 3.5× | (12.26%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.3× | (2.03%) |
| Mar 2026 | 2.4× | 32.73% |
| Dec 2025 | 1.8× | 93.53% |
| Sep 2025 | 0.9× | (43.60%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLIS Talis Biomedical Corporation compare | −55.3× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| RPID Rapid Micro Biosystems, Inc. compare | 1.0× |
| TELA TELA Bio, Inc. compare | 1.1× |
| MYO Myomo, Inc. compare | 1.2× |
| SNWV Sanuwave Health Inc. compare | 1.2× |
| SRTS Sensus Healthcare, Inc. | 2.1× |
| MDAI Spectral AI, Inc. compare | 3.0× |
| COCH Envoy Medical, Inc. compare | 390× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)